The role and clinical implications of microRNAs in hepatocellular carcinoma

Science China Life Sciences

Volumn 55, Issue 10, 2012, Pages 906-919

  Zhao, Xue ^a   Yang, Zhen ^b   Li, GuangBing ^a,c   Li, DongKai ^a   Zhao, Yi ^d   Wu, Yan ^e   Robson, Simon C ^e   He, Lian ^a   Xu, YiYao ^a   Miao, RuoYu ^a,d   Zhao, HaiTao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d INSTITUTE OF COMPUTING TECHNOLOGY   (China)

^e HARVARD UNIVERSITY   (United States)

Author keywords

cancer therapy; hepatocellular carcinoma; miRNA; noncoding RNAs

Indexed keywords

MICRORNA;

CHEMISTRY; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; REVIEW;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MICRORNAS;

HEPATITIS C VIRUS;

EID: 84868356989     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-012-4384-x     Document Type: Review

References (146)

1. Berry D A, Herbst R S, Rubin E H. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res, 2012, 18: 638-644.
2. Liu L, Miao R, Yang H, et al. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg, 2012, 203: 741-750.
3. El-Serag H B, Marrero J A, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology, 2008, 134: 1752-1763.
4. Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs, 2010, 15: 13-26.
5. Razumilava N, Gores G J. Sorafenib for HCC: a pragmatic perspective. Oncology (Williston Park), 2011, 25: 300, 302.
6. Blum H E. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol, 2005, 11: 7391-7400.
7. Cho Y K. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg, 2011, 254: 838-839.
8. Chen J W, Kow L, Verran D J, et al. Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. HPB (Oxford), 2009, 11: 81-89.
9. Calin G A, Croce C M. MicroRNA signatures in human cancers. Nat Rev Cancer, 2006, 6: 857-866.
10. Lu X, Zhao H, Yang H, et al. A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy. J Surg Oncol, 2009, 100: 488-493.
11. Clinkenbeard E L, Butler J E, Spear B T. Pericentral activity of AFP enhancer E3 and glutamine synthetase upstream enhancer in the adult liver are regulated by beta-catenin. Hepatology, 2012.
12. Petri A, Lindow M, Kauppinen S. MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res, 2009, 69: 393-395.
13. Mott J L. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology, 2009, 50: 630-637.
14. Feng Y, Yu X. Cardinal roles of miRNA in cardiac development and disease. Sci China Life Sci, 2011, 54: 1113-1120.
15. Zhang Y, Dong D, Yang B. Atrial remodeling in atrial fibrillation and association between microRNA network and atrial fibrillation. Sci China Life Sci, 2011, 54: 1097-1102.
16. Feng W, Feng Y. MicroRNAs in neural cell development and brain diseases. Sci China Life Sci, 2011, 54: 1103-1112.
17. Luo J, Teng M, Fan J, et al. Marek's disease virus-encoded microRNAs: genomics, expression and function. Sci China Life Sci, 2010, 53: 1174-1180.
18. Zuo J, Wang Y, Liu H, et al. MicroRNAs in tomato plants. Sci China Life Sci, 2011, 54: 599-605.
19. He S, Yang Z, Skogerbo G, et al. The properties and functions of virus encoded microRNA, siRNA, and other small noncoding RNAs. Crit Rev Microbiol, 2008, 34: 175-188.
20. Visone R, Petrocca F, Croce C M. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology, 2008, 135: 1866-1869.
21. Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci, 2002, 963: 13-20.
22. Yang C, Wei W. The miRNA expression profile of the uveal melanoma. Sci China Life Sci, 2011, 54: 351-358.
23. Wu J, Wang C, Du Z, et al. Identification of Pns12 as the second silencing suppressor of Rice gall dwarf virus. Sci China Life Sci, 2011, 54: 201-208.
24. Wang X, Zhao H, Xu Q, et al. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. Nucleic Acids Res, 2006, 34: D607-612.
25. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med, 2006, 147: 58-66.
26. Wang Y, Cui F, Lv Y, et al. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology, 2004, 39: 318-324.
27. Lara-Pezzi E, Majano P L, Yanez-Mo M, et al. Effect of the hepatitis B virus HBx protein on integrin-mediated adhesion to and migration on extracellular matrix. J Hepatol, 2001, 34: 409-415.
28. Xia L M, Huang W J, Wu J G, et al. HBx protein induces expression of MIG and increases migration of leukocytes through activation of NF-kappaB. Virology, 2009, 385: 335-342.
29. Chung T W, Lee Y C, Kim C H. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J, 2004, 18: 1123-1125.
30. Zhang F, Wang Q, Ye L, et al. Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-kappaB/p65 in hepatoma cells. J Med Virol, 2010, 82: 920-928.
31. Zhang X, Liu S, Hu T, et al. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology, 2009, 50: 490-499.
32. Yin Y, Zhao Y, Wang J, et al. antiCODE: a natural sense-antisense transcripts database. BMC Bioinformatics, 2007, 8: 319.
33. Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother, 2010, 64: 399-408.
34. Kitade Y, Akao Y. MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci, 2010, 114: 276-280.
35. Dasari V R, Kaur K, Velpula K K, et al. Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS ONE, 2010, 5: e10350.
36. Du B, Ma L M, Huang M B, et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett, 2010, 584: 811-816.
37. Narbus C M, Israelow B, Sourisseau M, et al. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol, 2011, 85: 12087-12092.
38. Cui Y, Su W Y, Xing J, et al. MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42. 3 in human gastric cancer. PLoS ONE, 2011, 6: e25872.
39. Dudek H, Datta S R, Franke T F, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 1997, 275: 661-665.
40. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133: 647-658.
41. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16: 498-509.
42. Kong G, Zhang J, Zhang S, et al. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS ONE, 2011, 6: e19518.
43. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem, 2005, 280: 37481-37488.
44. Irshad M, Dhar I. Hepatitis C virus core protein: an update on its molecular biology, cellular functions and clinical implications. Med Princ Pract, 2006, 15: 405-416.
45. Pedersen I M, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature, 2007, 449: 919-922.
46. Hou W, Tian Q, Zheng J, et al. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology, 2010, 51: 1494-1504.
47. Shan Y, Lambrecht R W, Ghaziani T, et al. Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAS. J Biol Chem, 2004, 279: 51769-51774.
48. Hornstein E, Mansfield J H, Yekta S, et al. The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development. Nature, 2005, 438: 671-674.
49. Kitamuro T, Takahashi K, Ogawa K, et al. Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J Biol Chem, 2003, 278: 9125-9133.
50. Shan Y, Zheng J, Lambrecht R W, et al. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology, 2007, 133: 1166-1174.
51. Zhu Z, Wilson A T, Mathahs M M, et al. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology, 2008, 48: 1430-1439.
52. Elbirt K K, Bonkovsky H L. Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians, 1999, 111: 438-447.
53. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 1999, 285: 110-113.
54. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol, 2004, 1: 106-113.
55. Lanford R E, Hildebrandt-Eriksen E S, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, 2010, 327: 198-201.
56. Wang G, Dong X, Hu J, et al. Long-term ex vivo monitoring of in vivo microRNA activity in liver using a secreted luciferase sensor. Sci China Life Sci, 2011, 54: 418-425.
57. Jopling C L, Norman K L, Sarnow P. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. Cold Spring Harb Symp Quant Biol, 2006, 71: 369-376.
58. Young D D, Connelly C M, Grohmann C, et al. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc, 2010, 132: 7976-7981.
59. Moradpour D, Penin F, Rice C M. Replication of hepatitis C virus. Nat Rev Microbiol, 2007, 5: 453-463.
60. Song Y, Friebe P, Tzima E, et al. The hepatitis C virus RNA 3′-untranslated region strongly enhances translation directed by the internal ribosome entry site. J Virol, 2006, 80: 11579-11588.
61. Bradrick S S, Walters R W, Gromeier M. The hepatitis C virus 3′-untranslated region or a poly(A) tract promote efficient translation subsequent to the initiation phase. Nucleic Acids Res, 2006, 34: 1293-1303.
62. Isken O, Baroth M, Grassmann C W, et al. Nuclear factors are involved in hepatitis C virus RNA replication. RNA, 2007, 13: 1675-1692.
63. Niepmann M. Activation of hepatitis C virus translation by a liver-specific microRNA. Cell Cycle, 2009, 8: 1473-1477.
64. Norman K L, Sarnow P. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J Virol, 2010, 84: 666-670.
65. Jopling C L, Yi M, Lancaster A M, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 2005, 309: 1577-1581.
66. Appel N, Bartenschlager R. A novel function for a micro RNA: negative regulators can do positive for the hepatitis C virus. Hepatology, 2006, 43: 612-615.
67. Banaudha K, Kaliszewski M, Korolnek T, et al. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology, 2011, 53: 53-61.
68. Nakada C, Matsuura K, Tsukamoto Y, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol, 2008, 216: 418-427.
69. Liu X, Wang T, Wakita T, et al. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology, 2010, 398: 57-67.
70. Yang Z, Ren F, Liu C, et al. dbDEMC: a database of differentially expressed miRNAs in human cancers. BMC Genomics, 2010, 11: S5.
71. Li H P, Leu Y W, Chang Y S. Epigenetic changes in virus-associated human cancers. Cell Res, 2005, 15: 262-271.
72. Huang J, Wang Y, Guo Y, et al. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology, 2010, 52: 60-70.
73. Datta J, Kutay H, Nasser M W, et al. Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res, 2008, 68: 5049-5058.
74. Law P T, Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol, 2011, 26: 437-449.
75. Shimizu S, Takehara T, Hikita H, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol, 2010, 52: 698-704.
76. Tsang W P, Kwok T T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem, 2010, 21: 140-146.
77. Tsuruta T, Kozaki K, Uesugi A, et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res, 2011, 71: 6450-6462.
78. Tsang T Y, Tang W Y, Chan J Y, et al. P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells. Apoptosis, 2011, 16: 524-535.
79. Sang X, Zhao H, Lu X, et al. Prediction and identification of tumor-specific noncoding RNAs from human UniGene. Med Oncol, 2010, 27: 894-898.
80. Chen W S, Leung C M, Pan H W, et al. Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. Oncol Rep, 2012, 28: 1069-1076.
81. Chung G E, Yoon J H, Myung S J, et al. High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. Oncol Rep, 2010, 23: 113-119.
82. Zhang Y. Progress, challenges and new concepts in microRNAs. Sci China Life Sci, 2011, 54: 1096.
83. Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA, 2010, 107: 264-269.
84. Xu C, Liu S, Fu H, et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer, 2010, 46: 2828-2836.
85. Furuta M, Kozaki K I, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis, 2010, 31: 766-776.
86. Zhao W Y, Wang D D, Song M Q, et al. Role of microRNA-223 and its target gene oncogene c-myc in hepatocellular carcinoma pathogenesis (in Chinese). Zhonghua Gan Zang Bing Za Zhi, 2011, 19: 114-117.
87. Cheng J, Zhou L, Xie Q F, et al. The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics, 2010, 10: 1557-1572.
88. Hu L, Ibrahim S, Liu C, et al. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res, 2009, 69: 3374-3381.
89. Fornari F, Milazzo M, Chieco P, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res, 2010, 70: 5184-5193.
90. Henry J C, Park J K, Jiang J, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun, 2010, 403: 120-125.
91. Orian-Rousseau V, Chen L, Sleeman J P, et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev, 2002, 16: 3074-3086.
92. Mitchell P S, Parkin R K, Kroh E M, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 2008, 105: 10513-10518.
93. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 2008, 18: 997-1006.
94. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE, 2008, 3: e3148.
95. Wang Q Z, Xu W, Habib N, et al. Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets, 2009, 9: 572-594.
96. Sukata T, Sumida K, Kushida M, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett, 2011, 200: 46-52.
97. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 2011, 29: 4781-4788.
98. Gui J, Tian Y, Wen X, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond), 2011, 120: 183-193.
99. Li L M, Hu Z B, Zhou Z X, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res, 2010, 70: 9798-9807.
100. Qu K Z, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol, 2011, 45: 355-360.
101. Li J, Wang Y, Yu W, et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun, 2011, 406: 70-73.
102. Miao R Y, Zhao H T, Yang H Y, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol, 2010, 16: 2931-2942.
103. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 2011, 50: 136-142.
104. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer, 2003, 39: 1990-2005.
105. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 2007, 129: 1401-1414.
106. Barshack I, Meiri E, Rosenwald S, et al. Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Biol, 2010, 42: 1355-1362.
107. Wong C C, Wong C M, Tung E K, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology, 2011, 140: 322-331.
108. Sato F, Hatano E, Kitamura K, et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS ONE, 2011, 6: e16435.
109. Wong Q W, Ching A K, Chan A W, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res, 2010, 16: 867-875.
110. Ji J, Zhao L, Budhu A, et al. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol, 2010, 52: 690-697.
111. Budhu A, Jia H L, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology, 2008, 47: 897-907.
112. Cheng A L, Kang Y K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10: 25-34.
113. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 2006, 66: 11851-11858.
114. Cominetti M R, Martin A C, Ribeiro J U, et al. Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen I under dynamic flow conditions. Biochimie, 2009, 91: 1045-1052.
115. Josson S, Anderson C S, Sung S Y, et al. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Prostate, 2011, 71: 232-240.
116. Peduto L. ADAM9 as a potential target molecule in cancer. Curr Pharm Des, 2009, 15: 2282-2287.
117. Xu Q, Liu X, Cai Y, et al. RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells. Tumour Biol, 2010, 31: 217-224.
118. Zhou C, Liu J, Li Y, e al. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett, 2011, 585: 1828-1834.
119. Bai S, Nasser M W, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem, 2009, 284: 32015-32027.
120. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 2009, 361: 1437-1447.
121. Calin G A, Dumitru C D, Shimizu M, et al. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 2002, 99: 15524-15529.
122. He L, Thomson J M, Hemann M T, et al. A microRNA polycistron as a potential human oncogene. Nature, 2005, 435: 828-833.
123. O'Donnell K A, Wentzel E A, Zeller K I, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 2005, 435: 839-843.
124. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem, 2006, 99: 671-678.
125. Jiang Q, Wang Y, Hao Y, et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res, 2009, 37: D98-104.
126. Sarver A L, Phalak R, Thayanithy V, et al. S-MED: sarcoma microRNA expression database. Lab Invest, 2010, 90: 753-761.
127. Calin G A, Sevignani C, Dumitru C D, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 2004, 101: 2999-3004.
128. Chen H, Chen Q, Fang M, et al. microRNA-181b targets MLK2 in HL-60 cells. Sci China Life Sci, 2010, 53: 101-106.
129. Lu J, Getz G, Miska E A, et al. MicroRNA expression profiles classify human cancers. Nature, 2005, 435: 834-838.
130. Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res, 2008, 36: D480-484.
131. Xiangji L, Feng X, Qingbao C, et al. Knockdown of HBV surface antigen gene expression by a lentiviral microRNA-based system inhibits HBV replication and HCC growth. J Viral Hepat, 2011, 18: 653-660.
132. Jin W B, Wu F L, Kong D, et al. HBV-encoded microRNA candidate and its target. Comput Biol Chem, 2007, 31: 124-126.
133. Ely A, Naidoo T, Mufamadi S, et al. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther, 2008, 16: 1105-1112.
134. Chen G, Wang C, Shi T. Overview of available methods for diverse RNA-Seq data analyses. Sci China Life Sci, 2011, 54: 1121-1128.
135. Qiu L, Fan H, Jin W, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun, 2010, 398: 771-777.
136. Li S, Yu B, Wang Y, et al. Identification and functional annotation of novel microRNAs in the proximal sciatic nerve after sciatic nerve transection. Sci China Life Sci, 2011, 54: 806-812.
137. Hao M, Zheng S, Ding H, et al. Regulation of microRNA-122 on HBV replication by targeting HBx sequence (in Chinese). Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 2011, 28: 784-789, 803.
138. Su C, Hou Z, Zhang C, et al. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J, 2011, 8: 354.
139. de Veer M J, Sledz C A, Williams B R. Detection of foreign RNA: implications for RNAi. Immunol Cell Biol, 2005, 83: 224-228.
140. Grimm D, Streetz K L, Jopling C L, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 2006, 441: 537-541.
141. Kim D H, Rossi J J. Strategies for silencing human disease using RNA interference. Nat Rev Genet, 2007, 8: 173-184.
142. Shah Y M, Morimura K, Yang Q, et al. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol, 2007, 27: 4238-4247.
143. Lan F F, Wang H, Chen Y C, et al. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). Int J Cancer, 2011, 128: 319-331.
144. Skawran B, Steinemann D, Becker T, et al. Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma. Mod Pathol, 2008, 21: 1479-1489.
145. Wu G, Yu F, Xiao Z, et al. Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. Br J Cancer, 2011, 105: 146-153.
146. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol, 2008, 173: 856-864.